| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Chia-Chi Lin; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; Shen Y.-C.; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:44Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano A.; Cassier P.A.; Chia-Chi Lin; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. |
| 臺大學術典藏 |
2022-03-15T05:39:21Z |
B cells are associated with survival and immunotherapy response in sarcoma
|
Petitprez F.; de Reyni?s A.; Keung E.Z.; WEI-WU CHEN; Sun C.-M.; Calderaro J.; Jeng Y.-M.; Hsiao L.-P.; Lacroix L.; Bougo?in A.; Moreira M.; Lacroix G.; Natario I.; Adam J.; Lucchesi C.; Laizet Y.; Toulmonde M.; Burgess M.A.; Bolejack V.; Reinke D.; Wani K.M.; Wang W.-L.; Lazar A.J.; Roland C.L.; Wargo J.A.; Italiano A.; Saut?s-Fridman C.; Tawbi H.A.; Fridman W.H. |
| 臺大學術典藏 |
2022-03-15T05:39:20Z |
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
|
Gounder M.; Sch?ffski P.; Jones R.L.; Agulnik M.; Cote G.M.; Villalobos V.M.; Attia S.; Chugh R.; WEI-WU CHEN; Jahan T.; Loggers E.T.; Gupta A.; Italiano A.; Demetri G.D.; Ratan R.; Davis L.E.; Mir O.; Dileo P.; Van Tine B.A.; Pressey J.G.; Lingaraj T.; Rajarethinam A.; Sierra L.; Agarwal S.; Stacchiotti S. |
| 臺大學術典藏 |
2022-03-15T05:39:18Z |
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
|
Frezza A.M.; Ravi V.; Lo Vullo S.; Vincenzi B.; Tolomeo F.; WEI-WU CHEN; Teterycz P.; Baldi G.G.; Italiano A.; Penel N.; Brunello A.; Duffaud F.; Hindi N.; Iwata S.; Smrke A.; Fedenko A.; Gelderblom H.; Van Der Graaf W.; Vozy A.; Connolly E.; Grassi M.; Benjamin R.S.; Broto J.-M.; Grignani G.; Jones R.L.; Kawai A.; Tysarowski A.; Mariani L.; Casali P.G.; Stacchiotti S. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 國立成功大學 |
2022 |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali, P.A.;Lin, C.-C.;Carthon, B.C.;Bauer, T.M.;Tucci, M.;Italiano, A.;Iacovelli, R.;Su, W.-C.;Massard, C.;Saleh, M.;Daniele, G.;Greystoke, A.;Gutierrez, M.;Pant, S.;Shen, Y.-C.;Perrino, M.;Meng, R.;Abbadessa, G.;Lee, H.;Dong, Y.;Chiron, M.;Wang, R.;Loumagne, Loumagne L.;L�pine, L�pine L.;De, Bono J. |
| 臺大學術典藏 |
2021-04-29T00:48:10Z |
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
|
Frezza A.M.; Ravi V.; Lo Vullo S.; Vincenzi B.; Tolomeo F.; WEI-WU CHEN; Teterycz P.; Baldi G.G.; Italiano A.; Penel N.; Brunello A.; Duffaud F.; Hindi N.; Iwata S.; Smrke A.; Fedenko A.; Gelderblom H.; Van Der Graaf W.; Vozy A.; Connolly E.; Grassi M.; Benjamin R.S.; Broto J.-M.; Grignani G.; Jones R.L.; Kawai A.; Tysarowski A.; Mariani L.; Casali P.G.; Stacchiotti S. |
